Halozyme Therapeutics Inc (NASDAQ:HALO)
| 18.98 Delayed Data As of Dec 13 |  +0.26 / +1.39%Today’s Change | 13.24 Today|||52-Week Range 19.73 | +29.73% Year-to-Date |
Latest HALO News | Press Releases
No recent news for Halozyme Therapeutics Inc.
Today’s Trading
| Previous close | 18.72 |
| Today’s open | 18.71 |
| Day’s range | 18.48 - 19.07 |
| Volume | 1,256,058 |
| Average volume (3 months) | 1,341,212 |
| Market cap | $2.8B |
Data as of 4:00pm ET, 12/13/2019
Growth & Valuation
| Earnings growth (last year) | -221.61% |
| Earnings growth (this year) | +26.20% |
| Earnings growth (next 5 years) | +55.00% |
| Revenue growth (last year) | -52.04% |
| P/E ratio | NM |
| Price/Sales | 13.83 |
| Price/Book | 11.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| KODKodiak Sciences Inc | +0.56 | +0.89% |
| BOLDAudentes Therapeutic... | +0.03 | +0.05% |
| EBSEmergent BioSolution... | -2.06 | -3.81% |
| XLRNAcceleron Pharma Inc | +0.54 | +1.08% |
Data as of 6:30pm ET, 12/13/2019
Financials
| Next reporting date | February 26, 2020 |
| EPS forecast (this quarter) | -$0.16 |
| Annual revenue (last year) | $151.9M |
| Annual profit (last year) | -$80.3M |
| Net profit margin | -52.90% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
